Aurobindo Pharma, Sandoz call off USD 900 mn dealIllustrative image – not actual.
Aurobindo Pharma’s USD 900 million deal to acquire Sandoz US-based generic oral solids and dermatology business has been mutually called off.

The decision was taken as approval from the US Federal Trade Commission for the transaction was not obtained within anticipated timelines.

In September 2018, Aurobindo Pharma’s US subsidiary entered into a pact to acquire commercial operations and three manufacturing facilities in America from Sandoz, USA, for USD 900 million. The acquisition was to be made through its wholly-owned subsidiary, Aurobindo Pharma USA.

The transaction if completed would have positioned the Hyderabad-based firm as the second largest dermatology company and the second largest generics company in the US by prescriptions.

← All latest storiesBack to top →